
    
      A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone
      density at 12 months in postmenopausal women with osteoporosis, and it significantly reduced
      the risk of vertebral fractures additionally.

      In this research, the efficacy and safety of generic zoledronic acid injection in the
      treatment of postmenopausal osteoporosis will be evaluated, using original drug as control
      drug. It will provide evidence for reasonable clinical administrations.
    
  